These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

314 related articles for article (PubMed ID: 26239001)

  • 1. Environment-contact administration of rotenone: A new rodent model of Parkinson's disease.
    Liu Y; Sun JD; Song LK; Li J; Chu SF; Yuan YH; Chen NH
    Behav Brain Res; 2015 Nov; 294():149-61. PubMed ID: 26239001
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Subcutaneous rotenone rat model of Parkinson's disease: Dose exploration study.
    Zhang ZN; Zhang JS; Xiang J; Yu ZH; Zhang W; Cai M; Li XT; Wu T; Li WW; Cai DF
    Brain Res; 2017 Jan; 1655():104-113. PubMed ID: 27876560
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neuroprotective effect of the antiparkinsonian drug pramipexole against nigrostriatal dopaminergic degeneration in rotenone-treated mice.
    Inden M; Kitamura Y; Tamaki A; Yanagida T; Shibaike T; Yamamoto A; Takata K; Yasui H; Taira T; Ariga H; Taniguchi T
    Neurochem Int; 2009 Dec; 55(8):760-7. PubMed ID: 19647776
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A highly reproducible rotenone model of Parkinson's disease.
    Cannon JR; Tapias V; Na HM; Honick AS; Drolet RE; Greenamyre JT
    Neurobiol Dis; 2009 May; 34(2):279-90. PubMed ID: 19385059
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Melatonin treatment potentiates neurodegeneration in a rat rotenone Parkinson's disease model.
    Tapias V; Cannon JR; Greenamyre JT
    J Neurosci Res; 2010 Feb; 88(2):420-7. PubMed ID: 19681169
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The rotenone-induced rat model of Parkinson's disease: behavioral and electrophysiological findings.
    von Wrangel C; Schwabe K; John N; Krauss JK; Alam M
    Behav Brain Res; 2015 Feb; 279():52-61. PubMed ID: 25446762
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chronic inhalation of rotenone or paraquat does not induce Parkinson's disease symptoms in mice or rats.
    Rojo AI; Cavada C; de Sagarra MR; Cuadrado A
    Exp Neurol; 2007 Nov; 208(1):120-6. PubMed ID: 17880941
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Development and characterisation of a novel rat model of Parkinson's disease induced by sequential intranigral administration of AAV-α-synuclein and the pesticide, rotenone.
    Mulcahy P; O'Doherty A; Paucard A; O'Brien T; Kirik D; Dowd E
    Neuroscience; 2012 Feb; 203():170-9. PubMed ID: 22198020
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Subcutaneous rotenone exposure causes highly selective dopaminergic degeneration and alpha-synuclein aggregation.
    Sherer TB; Kim JH; Betarbet R; Greenamyre JT
    Exp Neurol; 2003 Jan; 179(1):9-16. PubMed ID: 12504863
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Interaction between subclinical doses of the Parkinson's disease associated gene, α-synuclein, and the pesticide, rotenone, precipitates motor dysfunction and nigrostriatal neurodegeneration in rats.
    Naughton C; O'Toole D; Kirik D; Dowd E
    Behav Brain Res; 2017 Jan; 316():160-168. PubMed ID: 27585560
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Brain infusion of α-synuclein oligomers induces motor and non-motor Parkinson's disease-like symptoms in mice.
    Fortuna JTS; Gralle M; Beckman D; Neves FS; Diniz LP; Frost PS; Barros-Aragão F; Santos LE; Gonçalves RA; Romão L; Zamberlan DC; Soares FAA; Braga C; Foguel D; Gomes FCA; De Felice FG; Ferreira ST; Clarke JR; Figueiredo CP
    Behav Brain Res; 2017 Aug; 333():150-160. PubMed ID: 28668282
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term heat shock proteins (HSPs) induction by carbenoxolone improves hallmark features of Parkinson's disease in a rotenone-based model.
    Thakur P; Nehru B
    Neuropharmacology; 2014 Apr; 79():190-200. PubMed ID: 24296154
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bilateral upregulation of α-synuclein expression in the mouse substantia nigra by intracranial rotenone treatment.
    Carriere CH; Kang NH; Niles LP
    Exp Toxicol Pathol; 2017 Feb; 69(2):109-114. PubMed ID: 27986376
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neuroprotective and antidepressant-like effects of melatonin in a rotenone-induced Parkinson's disease model in rats.
    Bassani TB; Gradowski RW; Zaminelli T; Barbiero JK; Santiago RM; Boschen SL; da Cunha C; Lima MM; Andreatini R; Vital MA
    Brain Res; 2014 Dec; 1593():95-105. PubMed ID: 25301688
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CART modulates the effects of levodopa in rat model of Parkinson's disease.
    Upadhya MA; Shelkar GP; Subhedar NK; Kokare DM
    Behav Brain Res; 2016 Mar; 301():262-72. PubMed ID: 26771081
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Behavioral differences in a rotenone-induced hemiparkinsonian rat model developed following intranigral or median forebrain bundle infusion.
    Sindhu KM; Saravanan KS; Mohanakumar KP
    Brain Res; 2005 Jul; 1051(1-2):25-34. PubMed ID: 15992782
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nicotinic receptor stimulation protects nigral dopaminergic neurons in rotenone-induced Parkinson's disease models.
    Takeuchi H; Yanagida T; Inden M; Takata K; Kitamura Y; Yamakawa K; Sawada H; Izumi Y; Yamamoto N; Kihara T; Uemura K; Inoue H; Taniguchi T; Akaike A; Takahashi R; Shimohama S
    J Neurosci Res; 2009 Feb; 87(2):576-85. PubMed ID: 18803299
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neurodegeneration of mouse nigrostriatal dopaminergic system induced by repeated oral administration of rotenone is prevented by 4-phenylbutyrate, a chemical chaperone.
    Inden M; Kitamura Y; Takeuchi H; Yanagida T; Takata K; Kobayashi Y; Taniguchi T; Yoshimoto K; Kaneko M; Okuma Y; Taira T; Ariga H; Shimohama S
    J Neurochem; 2007 Jun; 101(6):1491-1504. PubMed ID: 17459145
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The behavioural and neuropathological impact of intranigral AAV-α-synuclein is exacerbated by systemic infusion of the Parkinson's disease-associated pesticide, rotenone, in rats.
    Mulcahy P; O'Doherty A; Paucard A; O'Brien T; Kirik D; Dowd E
    Behav Brain Res; 2013 Apr; 243():6-15. PubMed ID: 23295396
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Chronic Systemic Exposure to Low-Dose Rotenone Induced Central and Peripheral Neuropathology and Motor Deficits in Mice: Reproducible Animal Model of Parkinson's Disease.
    Miyazaki I; Isooka N; Imafuku F; Sun J; Kikuoka R; Furukawa C; Asanuma M
    Int J Mol Sci; 2020 May; 21(9):. PubMed ID: 32375371
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.